Revenue Growth
Sight Sciences reported total revenue of $19.1 million for Q4 2024, marking a 2% increase compared to the same period in the prior year.
Surgical Glaucoma Revenue Increase
Surgical glaucoma revenue grew by 9% in Q4 2024 compared to Q4 2023, driven by a 7% increase in ordering accounts and a 6% increase in account utilization.
Reduction in Net Cash Usage
The company achieved a 62% reduction in net cash used for FY 2024 compared to 2023, reflecting disciplined expense management.
Clinical Data and Advancements
Publication of three-year standalone clinical data for Omni and TearCare budget impact analysis, demonstrating effectiveness and potential cost savings.
Pipeline Development
Introduction of OMNI Edge planned for the first half of 2025, with enhancements in viscoelastic delivery designed to improve safety and efficacy.